BioPharm International November December 2025

The articles in this issue capture a sector balancing innovation with practicality as it prepares for the next generation of medicines.

Manufacturing biologics is a complex task. Mitigating risk early in the design of manufacturing facilities and the qualification of equipment minimizes future complications.

Microfluidic rapid-testing advances enhance real-time QC, strengthen compliance, and speed contamination detection across modern biomanufacturing.

With artificial intelligence and digital technologies transforming the CDMO space, industry leaders at CPHI Frankfurt shared their successes and identified pitfalls.

Performance advantages are driving adoption of membrane chromatography for advanced therapy purification.

Allogeneic CAR-T therapies deliver scalable, off-the-shelf cancer therapy, while autologous CAR-T therapies provide patient-specific but time-intensive treatment.